HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.

Abstract
Compounds possessing 5-HT(1A) agonist properties attenuate catalepsy induced by D(2) receptor blockade. Here we examined the role of 5-HT(1A) receptor agonism in the reduced cataleptogenic potential of several novel antipsychotic agents in the crossed leg position (CLP) and the bar catalepsy tests in rats. When administered alone, ziprasidone produced marked catalepsy, whereas aripiprazole, bifeprunox, SLV313, SSR181507 and sarizotan did not. However, when 5-HT(1A) receptors were blocked with the selective antagonist, WAY100635 (0.63 mg/kg, SC), robust cataleptogenic properties of SLV313, bifeprunox and sarizotan were unmasked and the catalepsy induced by ziprasidone was accentuated. In contrast, only modest catalepsy was induced by aripiprazole and SSR181507, even following a higher dose of WAY100635 (2.5 mg/kg). This suggests that these compounds possess other anti-cataleptic properties, such as partial agonism at dopamine D(2) receptors. The capacity to reverse neuroleptic-induced catalepsy was investigated in interaction studies with haloperidol (2.5 mg/kg, SC). Whereas ziprasidone and aripiprazole did not markedly reduce the effects of haloperidol, SLV313 and sarizotan attenuated CLP catalepsy. In contrast, SSR181507 and bifeprunox potently inhibited both CLP and bar catalepsy. Taken together, these data show that 5-HT(1A) receptor activation reduces the cataleptogenic potential of novel antipsychotic agents but indicate marked diversity in the contribution of 5-HT(1A) and/or other mechanisms to the profiles of the drugs.
AuthorsMark S Kleven, Catherine Barret-Grévoz, Liesbeth Bruins Slot, Adrian Newman-Tancredi
JournalNeuropharmacology (Neuropharmacology) Vol. 49 Issue 2 Pg. 135-43 (Aug 2005) ISSN: 0028-3908 [Print] England
PMID15996562 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-((5-(4-fluorophenyl)-3-pyridinyl)methyl)piperazine
  • Antiparkinson Agents
  • Antipsychotic Agents
  • Dopamine Antagonists
  • Organic Chemicals
  • Piperazines
  • Pyridines
  • Serotonin 5-HT1 Receptor Agonists
  • Serotonin Antagonists
  • Serotonin Receptor Agonists
  • Receptor, Serotonin, 5-HT1A
  • sarizotan
  • N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide
Topics
  • Analysis of Variance
  • Animals
  • Antiparkinson Agents (therapeutic use)
  • Antipsychotic Agents (therapeutic use)
  • Behavior, Animal
  • Catalepsy (chemically induced, drug therapy)
  • Dopamine Antagonists
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Male
  • Organic Chemicals
  • Piperazines (pharmacology, therapeutic use)
  • Pyridines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Serotonin, 5-HT1A (physiology)
  • Serotonin 5-HT1 Receptor Agonists
  • Serotonin Antagonists (pharmacology)
  • Serotonin Receptor Agonists (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: